cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine

Known as: Rituximab/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine, Rituxan/CHOP, Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone Regimen 
An abbreviation for a chemotherapy combination that is used to treat non-Hodgkin lymphoma and mantle cell lymphoma and is being studied in the… (More)

Topic mentions per year

Topic mentions per year

2001-2017
010020020012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
BACKGROUND Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Approximately 5% of diffuse large B-cell lymphomas (DLBCLs) are double-hit lymphomas (DHLs) with translocations of both… (More)
Is this relevant?
2011
2011
Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE The International Prognostic Index (IPI) is widely used for risk stratification of patients with aggressive B-cell… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in cancer patients with chronic HBV… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE To address early and late treatment failures in older patients with diffuse large B-cell lymphoma (DLBCL), we designed a… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Phase 2 studies suggest that the monoclonal antibody rituximab may improve the prognosis of patients with follicular lymphoma (FL… (More)
  • table 1
  • figure 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to moderate sensitivity to chemotherapy and a… (More)
Is this relevant?